Navigation Links
Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
Date:3/23/2011

GENEVA, March 23, 2011 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing, announced today the Company has completed the sequencing of their proprietary Chinese hamster ovary (CHO) cell line, the Selexis SURECHO-M Cell Line™. The project was performed in collaboration with the Institute of Biotechnology at the University of Lausanne, the SIB Swiss Institute of Bioinformatics and the CHUV, Centre Hospitalier Universitaire Vaudois (Lausanne University Hospital).

CHO cells are the leading industry choice for mammalian production of recombinant biologic therapeutic drugs. Approximately 70% of all recombinant therapeutic proteins and monoclonal antibodies (MAbs) are produced in CHO cells(1). Sales of these drugs exceed $30 billion USD annually. The proprietary Selexis SURECHO-M Cell Line is a high-performance suspension and serum-free adapted CHO cell line derived from the CHO-K1 lineage. The data from the sequencing of the Selexis SURECHO-M Cell Line will be used to generate detailed characterization packages of production clones for filings with regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, the data will be used to engineer the cell line's production capabilities in a predictable way.

"The Selexis SURECHO-M Cell Line genome data will be a valuable tool for helping our clients to improve their CMC documentation packages for regulatory filings with the FDA and EMA. In the near future, Selexis will be in a very strong position to utilize the data and genome sequence to engineer new CHO cell lines with defined specificities. More importantly, our engineered CHO cell lines will have enhanced expression capacity, especially for difficult to express recombinant proteins such as blood clot factors or fusion proteins, thus yielding therapeutics of higher quality," said Igor Fisch, CEO, Selexis SA. "The sequencing of our proprietary Selexis SURECHO-M Cell Line was a major accomplishment and a priority for Selexis in the continued improvement of our SURE Technology Platform."

Today, CHO cell lines used in the manufacturing of recombinant biologic therapeutics are from multiple origins and the variations between the CHO genomes are poorly understood. Additionally, the genetic characterization of genetically modified CHO cell lines producing recombinant protein drugs can still be quite challenging, especially when DNA amplification methods have been used to create the cell lines. Thus, regulatory agencies are increasingly looking towards more thorough filing packages. With the improvement of sequencing and genomics technologies, it is now possible to build a genomic map of particular manufacturing cell lines to finely characterize the genetic and production characteristics. Sequencing of the Selexis SURECHO-M Cell Line genome represents one of the first efforts to take genomic scale technology and apply it to industrial biologic manufacturing and regulatory activities.

Selexis and its academic collaborators will continue to work on the data analysis and genome assembly from this work. In addition to allowing more accurate manufacturing of therapeutics, this data will be used to advance the study of gene regulatory networks and expression in the Selexis SURECHO-M Cell Line as well as to improve the quantity and quality of its biologic production capabilities by cell and genome engineering.

About Selexis SURECHO-M Cell Line™

The Selexis SURECHO-M Cell Line is a proprietary high-performance mammalian cell line derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies. The growth and production properties of the Selexis SURECHO-M Cell Line are well defined and the feed strategy optimized allowing for faster scale-up into bioreactors. Therapeutics generated using the Selexis SURECHO-M Cell Line are in clinical trials in the United States and Europe.

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SURE Variant Screening™ and the proprietary Selexis SURECHO-M Cell Line™.

For more information, visit http://www.selexis.com

(1) CHO consortium - aiche.org/uploadedFiles/SBE/Publications/CHO.pdf

Contact:
Cammie Edwards, Ph.D.
Selexis SA
(650) 533-4667
cammie@dnagateway.com

Robert Meister
Selexis SA
602-953-1716
robert.meister@selexis.com


'/>"/>
SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. Selexis Launches Biosimilar Cell Line Development Program
4. China PharmaHub In-Licenses Universal Donor Red Blood Cells Technology Exclusively From University of California, San Diego
5. Mtech Announces Semifinalists for University of Maryland $75K Business Plan Competition
6. University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks
7. Queens University professor uses nanotechnology to prolong machine and engine life
8. Binghamton University nanoscientist chosen for the Air Forces Young Investigator Research Program
9. Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
10. Georgia Health Sciences University Clinical Study Shows RyMed InVision-Plus® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
11. Caliper Life Sciences Collaborates with University of Miami to Automate Next Generation Sequencing Workflows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... host a Key Opinion Leader event to highlight new ... and poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology ... event will be held in-person and via live webcast ... 9:00 AM PST at the Lotte New York Palace ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced today ... two key immunotherapy technologies from the University of ... a method to monitor a patient for response ... and CTLA-4.  The second license extends the technology ... is likely to have an immune-related adverse event ...
(Date:2/23/2017)... , ... February 23, 2017 ... ... announced today that in a published evaluation of multiple immunoassay-based threat detection ... Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found ...
(Date:2/23/2017)... SAN DIEGO , Feb. 23, 2017 /PRNewswire/ ... protein research tools, announced the acquisition of GenWay ... with a comprehensive service and product offering for ... "This acquisition will facilitate growth and enhance capabilities ... proteins, antibodies, and ELISA assays will nicely complement ...
Breaking Biology Technology:
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
(Date:1/21/2017)... DUBLIN , Jan 20, 2017 Research ... Recognition Biometrics Market 2017-2021" report to their offering. ... The global voice recognition ... period 2017-2021. The report covers the present scenario ... for 2017-2021. To calculate the market size, the report considers the ...
Breaking Biology News(10 mins):